We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
Zacks.com on MSN6d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
As of 16 September at 09:30 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.
With a volume of 492,652, the price of BNTX is up 6.46% at $111.78. RSI indicators hint that the underlying stock may be ...
2d
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback